Literature DB >> 26553439

Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?

Melissa Pilewskie1, Starr Koslow Mautner1, Michelle Stempel1, Anne Eaton2, Monica Morrow3.   

Abstract

BACKGROUND: American College of Surgeons Oncology Group (ACOSOG) Z0011 defined clinical node negativity by physical examination alone. Although axillary ultrasound with biopsy has a positive predictive value for lymph node (LN) metastases approaching 100 %, it may not appropriately identify clinically node-negative women with ≥3 positive LNs who require axillary lymph node dissection (ALND). We sought to identify the total number of positive LNs in women presenting with cT1-2N0 breast carcinoma with a positive preoperative LN biopsy to evaluate the potential for overtreatment when ALND is performed on the basis of a positive needle biopsy in patients who otherwise meet ACOSOG Z0011 eligibility criteria.
METHODS: Patients with cT1-2N0 breast cancer by physical examination with a positive preoperative LN biopsy were identified from a prospective institutional database. Clinicopathologic characteristics and axillary imaging results were compared between women with 1 to 2 total positive LNs and ≥3 total positive LNs.
RESULTS: Between May 2006 and December 2013, a total of 141 women with cT1-2N0 breast cancer had abnormal axillary imaging and a preoperative positive LN biopsy (median patient age 51 years, median tumor size 2.4 cm, 86 % ductal histology, 79 % estrogen receptor positive). Sixty-six women (47 %) had 1 to 2 total positive LNs, and 75 (53 %) had ≥3 total positive LNs. Women with ≥3 total positive LNs had larger tumors (2.4 vs. 2.2 cm, p = 0.03), fewer tumors with ductal histology (79 vs. 94 %, p = 0.01), more lymphovascular invasion (80 vs. 61 %, p = 0.01), and higher median body mass index (29.2 vs. 27.1 kg/m(2), p = 0.04). Having >1 abnormal LN on axillary imaging was significantly associated with having ≥3 total positive LNs at final pathology (68 vs. 43 %, p = 0.003).
CONCLUSIONS: Axillary imaging with preoperative LN biopsy does not accurately discriminate low- versus high-volume nodal disease in clinically node-negative patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26553439      PMCID: PMC4775411          DOI: 10.1245/s10434-015-4944-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Clinical utility of routine pre-operative axillary ultrasound and fine needle aspiration cytology in patient selection for sentinel lymph node biopsy.

Authors:  T Rattay; M Muttalib; E Khalifa; A Duncan; S J Parker
Journal:  Breast       Date:  2011-10-05       Impact factor: 4.380

2.  Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.

Authors:  Armando E Giuliano; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow; Karla Ballman
Journal:  Ann Surg       Date:  2010-09       Impact factor: 12.969

3.  Preoperative axillary imaging with percutaneous lymph node biopsy is valuable in the contemporary management of patients with breast cancer.

Authors:  Tina J Hieken; Brent C Trull; Judy C Boughey; Katie N Jones; Carol A Reynolds; Sejal S Shah; Katrina N Glazebrook
Journal:  Surgery       Date:  2013-10       Impact factor: 3.982

Review 4.  Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer.

Authors:  B J van Wely; J H W de Wilt; C Francissen; S Teerenstra; L J A Strobbe
Journal:  Br J Surg       Date:  2014-10-29       Impact factor: 6.939

5.  Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla.

Authors:  Nehmat Houssami; Stefano Ciatto; Robin M Turner; Hiram S Cody; Petra Macaskill
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

Review 6.  Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.

Authors:  Miraj Shah-Khan; Judy C Boughey
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

7.  Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value?

Authors:  R J Schipper; L M van Roozendaal; B de Vries; R M Pijnappel; R G H Beets-Tan; M B I Lobbes; M L Smidt
Journal:  Breast       Date:  2013-10-02       Impact factor: 4.380

8.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

Review 9.  Axillary node interventions in breast cancer: a systematic review.

Authors:  Roshni Rao; David Euhus; Helen G Mayo; Charles Balch
Journal:  JAMA       Date:  2013-10-02       Impact factor: 56.272

10.  Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000.

Authors:  Montserrat Solá; José A Alberro; Manuel Fraile; Pilar Santesteban; Manuel Ramos; Rafael Fabregas; Antonio Moral; Blas Ballester; Sergi Vidal
Journal:  Ann Surg Oncol       Date:  2012-09-07       Impact factor: 5.344

View more
  25 in total

1.  Minimal Invasive and Individualizing Management of the Axillary Nodes.

Authors:  Jun Won Min; Jihyoung Cho
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Utility of Preoperative Staging of Ipsilateral Axilla with Ultrasound and Guided Needle Aspiration in Early-Stage Breast Cancer-Current Indian Scenario.

Authors:  Balasubramanian Venkitaraman; Kajamohideen Suhailudeen
Journal:  Indian J Surg Oncol       Date:  2018-07-26

3.  Evaluation of axillary lymph node metastasis burden by preoperative ultrasound in early-stage breast cancer with needle biopsy-proven metastasis.

Authors:  X Wang; L Chen; Y Sun; B Zhang
Journal:  Clin Transl Oncol       Date:  2019-06-18       Impact factor: 3.405

4.  Lymph Node Surgery - Stepwise Retirement for the Breast Surgeon?

Authors:  Julia Landin; Walter P Weber
Journal:  Breast Care (Basel)       Date:  2016-08-22       Impact factor: 2.860

5.  Implications of abnormal preoperative axillary imaging in the post Z011 era.

Authors:  Matthew Selleck; Maheswari Senthil
Journal:  Gland Surg       Date:  2016-06

6.  Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.

Authors:  Monica Morrow; Kimberly J Van Zee; Sujata Patil; Oriana Petruolo; Anita Mamtani; Andrea V Barrio; Deborah Capko; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Laurie Kirstein; Melissa Pilewskie; George Plitas; Virgilio S Sacchini; Lisa M Sclafani; Alice Ho; Hiram S Cody
Journal:  Ann Surg       Date:  2017-09       Impact factor: 12.969

7.  Impact of Body Mass Index on Clinical Axillary Nodal Assessment in Breast Cancer Patients.

Authors:  Damian McCartan; Michelle Stempel; Anne Eaton; Monica Morrow; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2016-06-23       Impact factor: 5.344

Review 8.  Management of the Node-Positive Axilla in Breast Cancer in 2017: Selecting the Right Option.

Authors:  Monica Morrow
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

9.  Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Kenneth Hess; Lumarie Santiago; Deanna L Lane; Alastair M Thompson; Stacy L Moulder; Monica L Huang; Elsa M Arribas; Gaiane M Rauch; Jessica W T Leung; W Fraser Symmans; Vicente Valero; Elizabeth E Ravenberg; Jason B White; Wei Tse Yang
Journal:  Eur J Radiol       Date:  2020-07-10       Impact factor: 3.528

Review 10.  Overview of Breast Cancer Therapy.

Authors:  Tracy-Ann Moo; Rachel Sanford; Chau Dang; Monica Morrow
Journal:  PET Clin       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.